The anti-PD-1 monoclonal antibody JS001 of Junshi has been completed the first patient administration of Phase I clinical trial in the U.S. several days ago, which has aroused wide attention from the insiders. What are currently the hottest star drugs in the pharmaceutical industry? Anti-PD-1/PD-L1 drugs are definitely one among them, with any news able to shake the industry. Today, I’d like to make the most comprehensive summary ever and talk about anti-PD-1/PD-L1 drugs.
Anti-PD-1/PD-L1 drugs will occupy two positions among the Top 5 in global drug sales in the future
According to EvaluatePharma’s forecast of rankings of global drug sales in 2022 not long ago, the monoclonal antibody drug Opdivo and Keytruda that target PD-1 enter the Top 5 upon good therapeutic effect and multiple indications, with annual sales to separately approach USD 10 billion.
EvaluatePharma’s Forecast of Top 5 in Global Drug Sales in 2022